Amylyx has announced the appointment of Andrew Caldwell as General Manager UK and Ireland.
He joins the company with more than 30 years of life sciences industry experience including a decade spent in the commercialisation of rare and specialised disease therapies in the UK and Ireland.
Andrew has previously established and grown UK and Ireland-focused business entities for neurodegenerative disease specialist Orphazyme, and Akcea Therapeutics. He was also a former commercial lead for Alexion Pharmaceuticals and a core member of Merck Serono’s UK senior leadership team.
“Working as part of the Amylyx EMEA team, I’m determined to help advance our position in motor neurone disease, which has had no new treatment option in Europe for more than 25 years. Alongside this, I’m excited to be part of Amylyx’ progress in addressing other neurodegenerative diseases,” said Andrew.
